(Nasdaq: TLSA) Triggers Friday's Early AM Radar (Huge News This Week And A Boosted Analyst Target)

We're on a heater this week.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: TLSA) Triggers Friday's Early AM Radar (Huge News This Week And A Boosted Analyst Target) *Click Here To Get Our Alerts Faster Via SMS* May 22nd Greetings Readers, We're on a heater this week. In fact, Thursday's profile showed off in a major way. Surging to a high of $5.36 after closing the previous day at $4.43, that Nasdaq idea popped vertically quickly. All in all, the short term run resulted in a move of approx. 20%. That comes on the heels of a 2-day runner that moved to a new 3+ month high of $1.70 on Thursday following Tuesday's close of $1.26. When the dust settled, that short term move of approx. 34% confirmed another breakout star. With breakthroughs in neurodegenerative disease treatment accelerating, one under-the-radar company has popped up on our radar with the Alzheimer’s therapy market is projected to exceed $15Bn by 2030 and multiple sclerosis treatments expected to surpass $35Bn globally. And following two key developments this week (boosted analyst target and a "pivotal" company moment), this Nasdaq idea is topping our watchlist Friday: Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. The Company's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. And based on several potential catalysts, (Nasdaq: TLSA) has taken over the top spot on my watchlist. Check them out: #1. A Major News Announcement This Week Represents A "Pivotal Moment" For The Company. #2. An Analyst $9 Target Suggests Triple-Digit Potential Upside From Current Chart Levels. #3. Announced Positive Clinical Data Demonstrate Foralumab Continues To Be Extremely Well Tolerated Over Extended Treatment Durations. #4. The Company's Phase 2 Clinical Trial For Foralumab Shows Marked Reduction In Inflammation On PET Scans. #5. More Positive Data Announced In A Key Publication (Supports Therapeutic Potential Of Lead Candidate). But more on those in a second... Tiziana Life Science Full Company Breakdown Tiziana Life Sciences is a clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and neuroinflammatory. Their clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer’s, and ALS. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. Company Background Tiziana's mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The Company's lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Foralumab is the only fully human anti-CD3 monoclonal antibody under clinical development and is expected to minimize adverse immune responses in patients. Tiziana has submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival. The Company employs a lean and virtual research and development model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes. Corporate Strategy -- Continue the clinical development of intranasal administration of Foralumab for neurodegenerative disease indications: Secondary Progressive, Multiple Sclerosis Alzheimer’s Amyotrophic Lateral Sclerosis (ALS) -- Commence Phase 2 clinical trial after successfully receiving their Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients. -- Submit an Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients. -- Seek orphan drugs fast track or breakthrough designation for the Company's product candidates where warranted. Intranasal Foralumab Pipeline Grab Sources And More: TLSA Website. TLSA Presentation. ----- And as I mentioned previously, (Nasdaq: TLSA) has several potential catalysts we're tracking. Check them out:  #1. TLSA Potential Catalyst - A Major News Announcement This Week Represents A "Pivotal Moment" For The Company. Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026. The trial (NCT06292923), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this novel anti-CD3 monoclonal antibody for neurodegenerative and neuroinflammatory diseases. The multicenter study has enrolled 48 patients across multiple leading U.S. sites to receive one of two doses of intranasal foralumab or placebo over a 12-week treatment period, with assessments including PET imaging for microglial activation, MRI, clinical evaluations, and biomarkers. Following the completion of the blinded phase, all participants including those who initially received placebo will have the opportunity to receive intranasal foralumab during a six-month open label extension (OLE) phase. The OLE is designed to assess long term safety and sustained benefit of foralumab in the na-SPMS patient population. “This completion of enrollment in our Phase 2a trial represents a pivotal moment for Tiziana Life Sciences and for patients suffering from na-SPMS, a condition with limited treatment options,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “As the first placebo-controlled trial of intranasal foralumab, this study underscores our commitment to rigorously evaluating this innovative therapy’s potential to modulate the immune system and address neuroinflammation. We are grateful for the dedication of our clinical partners and look forward to sharing topline results that could pave the way for a new treatment paradigm.” ... Read the full article here. ----- #2. TLSA Potential Catalyst - An Analyst $9 Target Suggests Triple-Digit Potential Upside From Current Chart Levels. This week, Lucid Capital Markets provided a key update on TLSA. In the update, Lucid reiterated an $9.00 target on TLSA. From Thursay's close, that target represents a potential 475+% upside. Report highlights: Tiziana Life Sciences (TLSA) reported long-term data from its multiple sclerosis expanded access program, indicating disease stabilization and reduction in fatigue, along with initial PET imaging data from a novel indication: Multiple System Atrophy (MSA). We are increasingly confident on the potential success of foralumab in multiple neuroinflammatory conditions. Therefore, ..., but increase our 12-month price target from $8 to $9/share. ----- #3. TLSA Potential Catalyst - Announced Positive Clinical Data Demonstrate Foralumab Continues To Be Extremely Well Tolerated Over Extended Treatment Durations. Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated clinical data from its ongoing Expanded Access ("EA") Program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The data, updated from March 2025 to as of March 2026, demonstrate that intranasal foralumab continues to be extremely well tolerated over extended treatment durations. Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale (EDSS) and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale (MFIS). ... Dr. Howard L. Weiner, Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, and Chair of the Scientific Advisory Board of Tiziana Life Sciences, commented: "These longer-term results from the Expanded Access SPMS Program continue to support the potential of intranasal foralumab as a novel, immunomodulatory therapy for patients with non-active SPMS. The excellent tolerability profile combined with trends toward disability stabilization and fatigue improvement is highly encouraging and warrants further investigation." Ivor Elrifi, CEO of Tiziana Life Sciences, added: "We are pleased with the continued positive safety and clinical trend data from our Expanded Access Program. Intranasal foralumab's unique mechanism, which reduces neuroinflammation, positions it as a potential new treatment paradigm for progressive forms of multiple sclerosis where treatment options remain limited. We look forward to advancing this program to approval." Read the full article here. ----- #4. TLSA Potential Catalyst - The Company's Phase 2 Clinical Trial For Foralumab Shows Marked Reduction In Inflammation On PET Scans. Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab. Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to be affected in MSA following treatment with intranasal foralumab. In the first two treated patients, investigators observed up to approximately 35% reduction in standardized uptake value (SUV) and approximately 24% reduction in standardized uptake value ratio (SUVR) in affected areas of the brain. ... “These early PET imaging findings provide quantitative evidence supporting the biological activity of intranasal foralumab in patients with MSA,” said Tarun Singhal, MBBS, M.D., Founding Director, NeuroPET Program, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Mass General Brigham. “In the first two MSA patients we evaluated, we observed up to approximately 35% reduction in standardized uptake value and a 24% reduction in SUV ratio in the affected brain regions. We focused on the most severely affected, clinically relevant areas known to be involved in MSA. Based on the available data, these appear to be robust quantitative findings and are comparable to results previously observed in patients with multiple sclerosis treated with intranasal foralumab, although there are methodological differences.” “This is the third indication that we have seen a marked reduction in inflammation on PET scans following treatment with intranasal foralumab,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “Building on the encouraging results previously reported in non-active secondary progressive multiple sclerosis and moderate Alzheimer’s disease, these initial MSA data further highlight the potential of our therapy to meaningfully address neuroinflammation across multiple neurodegenerative conditions with high unmet need.” ... Read the full article here. ----- #5. TLSA Potential Catalyst - More Positive Data Announced In A Key Publication (Supports Therapeutic Potential Of Lead Candidate). Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long CVD Neuroinflammation and Improves Cognitive Function Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long CVD associated “brain fog." BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the publication of positive preclinical data in a bioRxiv preprint. The study, titled “Intranasal Anti-CD3 Antibody Treatment Attenuates Post CVD Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice,” demonstrates that nasal anti-CD3 treatment significantly reduces neuroinflammation, boosts regulatory T cells (Tregs) in the brain, restores hippocampal neurogenesis, and improves short-term memory in a model of Long CVD. ... These findings show that nasal anti-CD3 can potently induce regulatory T cells that cross into the brain and dampen persistent neuroinflammation triggered by even mild respiratory viral infection. By reprogramming microglia, reducing harmful chemokines like CCL11, and restoring the hippocampal neurogenic niche, this approach offers a promising, non-invasive strategy to address the cognitive impairment often called ‘brain fog’ that continues to affect millions of Long CVD patients worldwide. ... Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented: “We are thrilled to see these robust preclinical data in BioRxiv, further validating the broad therapeutic potential of our intranasal foralumab platform. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, and these results directly support the mechanistic foundation for our ongoing programs in non active secondary progressive multiple sclerosis, MSA, Alzheimer’s disease, and ALS.” ... Read the full article here. ----- (Nasdaq: TLSA) Recap - 5 Potential Catalysts On Our Radar #1. A Major News Announcement This Week Represents A "Pivotal Moment" For The Company. #2. An Analyst $9 Target Suggests Triple-Digit Potential Upside From Current Chart Levels. #3. Announced Positive Clinical Data Demonstrate Foralumab Continues To Be Extremely Well Tolerated Over Extended Treatment Durations. #4. The Company's Phase 2 Clinical Trial For Foralumab Shows Marked Reduction In Inflammation On PET Scans. #5. More Positive Data Announced In A Key Publication (Supports Therapeutic Potential Of Lead Candidate). ----- Coverage is officially underway on Tiziana Life Sciences, Ltd. (Nasdaq: TLSA). Updates will be coming down the wire soon. Talk shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/22/2026 and ending on 05/22/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the forty seven thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (TLSA:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/tlsa-vconj/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice

ALERT UPDATE: Washington Just Hit Quantum With $2 Billion

Washington is running the same playbook that turned $52B into $200B.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

May 22nd, 2026   |   Read online   Donald Doge Two weeks ago I told you the procurement dollars were coming. Yesterday, $2 billion showed up. The U.S. Department of Commerce signed letters of intent with nine quantum computing companies Thursday, funded by the same CHIPS and Science Act I used as the lead example in the essay below. IBM is receiving $1 billion to launch a company called Anderon in Albany, New York. Anderon will be America's first dedicated quantum chip factory, a 300-millimeter wafer foundry purpose-built for quantum hardware. IBM is matching the federal billion with a billion of its own cash, intellectual property, and workforce. That is $2 billion committed to a single manufacturing facility before the first wafer comes off the line. GlobalFoundries is receiving $375 million to stand up a new Quantum Technology Solutions division. D-Wave, Rigetti, and Infleqtion are each receiving roughly $100 million. An Australian silicon-spin startup called Diraq is getting $38 million. Quantum stocks jumped between 3% and 24% by midday Thursday. IBM closed up 7%. In the essay below, I walked you through three historical spending waves triggered by bipartisan tech legislation. CHIPS put $52 billion on the table and triggered over $200 billion in private investment. Intel broke ground on a $20 billion complex in Ohio. Samsung put $17 billion into Texas. TSMC expanded in Arizona. Yesterday's quantum deals follow the identical playbook. The government is taking minority equity stakes in all nine companies, the same structure used in the Intel CHIPS award last August, where the administration converted federal incentives into a roughly 10% ownership position. The Council on Foreign Relations called that Intel deal one of the most profitable government investments in American industrial history. Yesterday, the same mechanism was applied to quantum. When Washington takes ownership instead of writing a check, private capital follows because government equity is a quality signal to every institutional investor watching. That is how $52 billion turned into $200 billion the last time around. Every Bank, Every Broker, Same Deadline NIST, the federal agency that sets the encryption standards every bank, brokerage, and defense contractor must follow, advanced nine new post-quantum cryptographic algorithms to the third round of its standardization process. The replacement locks I described in the original Q-Day essay are being built right now. The encryption protecting your brokerage login, your bank wire, and your retirement savings will eventually be rebuilt on whatever NIST selects from this process. Every regulated institution in the country will need products built on those standards before the compliance deadlines hit. The Commerce Department is funding the companies building the quantum machines. NIST is standardizing the encryption those machines will force the world to replace. The NSA's January 2027 mandate, the G7's 2027-2034 migration window, and the EU's December 2030 deadline are all intact. The spending to meet those deadlines started moving yesterday. And private capital is not waiting for the legislation to clear the full Senate. Quantinuum, the quantum computing company majority-owned by Honeywell with backing from Nvidia, JPMorgan Chase, Fidelity, and Amgen, filed for a Nasdaq IPO under the ticker QNT earlier this month. J.P. Morgan and Morgan Stanley are running the books. The largest quantum pure-play in the world is going public into a market where the federal government just committed $2 billion in a single day. Xanadu, a photonic quantum computing company, debuted on Nasdaq last week with a 304% revenue increase and $285 million in government funding negotiations underway. Multiple quantum companies have gone public in 2026, with more in the pipeline. Every major quantum hardware company is now either receiving federal funding, going public, or both. That has never happened before in this sector. $2 Billion in Thirteen Days The last two weeks, in sequence: May 8: I published the Q-Day essay, mapping the four research lanes and the companies building the replacement locks for the post-quantum world. May 13: I published the essay below, connecting the congressional signal to three historical spending waves and laying out the compliance deadlines that would force the money to move. May 14: The NSF launched a $1.5 billion X-Labs initiative. Its first two funding tracks target quantum systems directly. May 15: A name from our quantum research entered the Premium portfolio with a specific entry price, buy-under level, and position sizing. May 21: The Commerce Department committed $2 billion to nine quantum companies and took equity stakes. NIST advanced nine post-quantum algorithms. Quantum stocks surged across the board. Premium members: scroll down past the essay below for a quick portfolio update. Yesterday was a good day for us. If you are reading this as a free subscriber to Moonshot Minute, what you just received is the thesis. The spending patterns, the compliance deadlines, the three historical precedents, and the framework for identifying which companies will capture the spending wave. The essay below lays it all out. It went out nine days ago. Yesterday the federal government validated our thesis with $2 billion and an equity-stake structure identical to the one that turned CHIPS into the most profitable government investment in modern history. That is what the free list gets: the thinking, the framework, and research you will not find in a single mainstream article about yesterday's announcement. None of them are connecting the Q-Day encryption timeline to the federal procurement timeline to the specific companies positioned to capture both. We are. Premium is where the names, entry prices, and timing live. On May 15, six trading days before the Commerce Department committed $2 billion to the quantum supply chain, a name from our quantum research entered the Premium portfolio. Premium members had the ticker, the entry price, the buy-under level, the position sizing, and the full thesis write-up. The position was already in the green before yesterday's news broke. After the announcement, the sector moved further. As of this writing, it is still within buy range. That is what a research process looks like when it works. And the quantum name is one position in a portfolio that currently holds six Moonshot Rides. Each of those six positions doubled from entry, the original investment was recovered in full, and the remaining shares are riding with zero capital at risk. Four open positions are above 100% right now, including one at 183%. Twelve closed trades have hit the books since launch, every one a winner, with an average gain north of 70%. The quantum thesis is still early. The research pipeline has more names. When they clear our filters, Premium members see them first. If you want the names behind the thesis you just read, the link is below. Double D Below is the original essay from May 13, 2026: "Congress just agreed: $200B flowed last time this happened" On Friday, May 8, I told you about Q-Day, the moment quantum computers become powerful enough to break the encryption protecting your bank account, your brokerage, your retirement savings, and every classified database on the planet. Monday, I told you that one of the companies the Moonshot Minute editorial team has been researching in that space got significantly cheaper, for reasons that had nothing to do with the quantum thesis. Today is about where the money is going. Because while the market was focused on earnings headlines and tariff noise last week, something happened in Washington that almost nobody covered. The Senate Commerce Committee passed the National Quantum Initiative Reauthorization Act without a single dissenting vote. In a Congress that has spent years fighting over everything from government funding to social media regulation, quantum security cleared committee with zero opposition. Google endorsed the bill publicly. So did Microsoft, IBM, D-Wave, and a half-dozen quantum startups. Bipartisan co-sponsors, bipartisan industry support, and no debate. I've been in the financial publishing business long enough to know that when both parties agree on something with that kind of speed and that little friction, it tells me one thing: the procurement dollars are coming. All we have to do is position ourselves in front of the wave. And I have the receipts. Three Times Congress Agreed. Three Spending Waves That Followed Let’s have a quick look at the last three times tech and infrastructure received either unanimous or overwhelming support. CHIPS and Science Act, 2022.  Passed the Senate 64 to 33. Bipartisan. Authorized $280 billion, with $52 billion in direct subsidies for domestic semiconductor manufacturing. Within two years, private industry had committed between $160 and $200 billion in new investment. Intel broke ground on a $20 billion complex in Ohio that could reach $100 billion. Samsung put $17 billion into Texas. TSMC expanded in Arizona. The federal government put up $52 billion and unlocked four times that amount in private capital. One semiconductor name in the Moonshot Minute portfolio doubled on that buildout, and today its shares are still climbing, up almost 150%. Infrastructure Investment and Jobs Act, 2021.  Passed the Senate 69 to 30, with 19 Republican senators crossing the aisle. $1.2 trillion for roads, bridges, broadband, the power grid, and EV charging infrastructure. One grid infrastructure name in the Moonshot Minute portfolio is up over 55% since we added it in February, riding the exact buildout that legislation funded. Cybersecurity Information Sharing Act, 2015.  Passed the Senate 74 to 21. Created the legal framework for companies to share cybersecurity threat intelligence with the federal government without fear of lawsuits. Before that law, most companies sat on breach data. After it passed, cybersecurity spending went from roughly $75 billion to over $200 billion in less than a decade. CrowdStrike, Palo Alto, Fortinet, Zscaler, the entire modern cybersecurity industry was built on the infrastructure that vote created. The Stryker attack I wrote about in late March happened inside the world this law built, and that thesis led to a cybersecurity name being added to the Moonshot Minute portfolio and it’s now up almost 20% in a few weeks. These three votes alone triggered three spending waves totaling hundreds of billions. The Moonshot Minute portfolio was positioned ahead of all three each time and it’s one of the reasons why our subscribers stick around for so long. And now, the quantum reauthorization just cleared committee the same way. Today, we're adding our first name in the space to the Moonshot Minute watchlist because the pattern is the same, and Premium Members benefited greatly each time this happened. Our only job is getting in front of the capital before it arrives. The First Deadline Is Just 8 Months Away The quantum spending that’s coming is already baked into compliance calendars. The deadlines are set, and the first one is eight months away. The NSA's hard mandate. The NSA's updated security framework, called CNSA 2.0, requires all new national security systems to use quantum-safe encryption algorithms by January 2027. Every defense contractor, government IT vendor, and every system that touches classified networks must comply. New acquisitions after that date must be quantum-proof or they don't get approved. Full migration of legacy systems is required by 2030 to 2035. The G7 financial roadmap. In January, the G7 Cyber Expert Group, co-chaired by the U.S. Treasury and the Bank of England, published a roadmap for the financial sector. The core migration execution window runs from 2027 to 2034. That means your bank, your brokerage, and your payment processor are all expected to begin moving to quantum-resistant encryption within the next 18 months. The G7 doesn't make suggestions. When the U.S. Treasury and the Bank of England co-sign a migration timeline, the compliance machinery follows and is mandatory. The EU deadline. EU member states are required to have national post-quantum strategies and cryptographic inventories completed by December 31, 2026. Critical financial systems, including banking infrastructure, must be migrated to quantum-resistant cryptography by December 31, 2030. The picture we have here shows three regulatory bodies, with three overlapping timelines, and all converging on the same window. How much spending are we talking about? An institutional research firm published a note this week estimating that direct post-quantum cryptography spending could reach $3 to $8 billion by 2030. However, that covers the encryption products themselves. The total infrastructure spend those migrations trigger, the hardware upgrades, the compliance audits, the system overhauls across every bank, brokerage, and defense contractor the mandates touch, will be many multiples of that number. We've seen this before. The CHIPS Act put $52 billion on the table and unlocked $200 billion in private capital. Cybersecurity spending quadrupled in the decade after the 2015 information-sharing law passed. Initial estimates in compliance-driven spending cycles consistently undercount the total ecosystem impact because they measure the product, not the buildout around it. This is that kind of cycle. It arrives because the deadline arrives. The Tools Don't Exist Yet As of early 2026, no vendor has completed the production certification required to run quantum-proof encryption in the hardware that secures regulated payment systems. Every credit card swipe, every bank wire, every settlement in the country runs through that hardware, and it cannot currently execute the new encryption math in a way that meets regulatory standards. The first certified systems may not arrive until 2027. The central banks already know this. The Bank for International Settlements ran a pilot project in 2025 called Project Leap, testing post-quantum cryptography in payment systems between central banks. The institutions at the top of the financial system are testing because they know the infrastructure underneath is exposed. The question is whether the institutions holding your money, the regional banks, the smaller brokerages, the fintech apps you use day to day, can keep up. The NSA says January 2027. The G7 says 2027 to 2034. The EU says December 2030. Most of those institutions fall into the 90% that Bain research found had no migration plan at all. New Watchlist Addition The editorial team has been tracking this space for some time now. Last week’s essay mapped the four areas of research we’re focused on. In Monday's email, I explained that some of those names got significantly cheaper for reasons that had nothing to do with the quantum thesis. Today we're adding that company to the Moonshot Minute watchlist. Below in the Premium section, Premium Members will find the name, our initial write-up on the company, why it landed on the watchlist now, and the specific conditions that will trigger a buy alert. This is not a buy recommendation. The entry has to be right and this week the markets are behaving erratically. But the research has passed enough of our filters that Premium readers deserve to see where we are and what we're watching for. That discipline is how the portfolio got to where it is. We don't rush entries. The watchlist is where names live until the setup is clean, and Premium readers get to watch the process in real time so they're ready to act the moment the alert drops. The results of that process over the past six weeks: a 42% gain on a takeover, three consecutive triple-digit closes, and a 137% exit on a position held just under ten months. Twelve closed positions total, twelve winners, zero losses. The average gain across all closed trades sits around 74%. Five positions doubled, got trimmed back to original cost basis, and are still climbing on house money. Premium members have zero capital at risk in those names and pure upside from here. The quantum watchlist name is being held to the same standard. When the entry is right, Premium readers hear first. What To Do This Week Call your broker. Call your bank. Ask them one question: what is your plan for post-quantum encryption? Most of them won't know what you're talking about. Some will give you a vague answer about "monitoring developments." A few, at the largest institutions, might have a real response. The answer you get will tell you exactly where your money sits on the readiness spectrum. And if the answer is silence, you'll understand why we’ve been spending so much time in this space. Q-Day is coming. Washington is preparing, Wall Street is waking up, and the compliance clock is already running. The only question is whether the institutions holding your money will be ready, and whether you'll be positioned on the right side of the wave. Double D P.S. Here’s a screenshot of the current Moonshot Minute Portfolio. I’ve blurred out the tickers since that information is only for Premium Members, but you can see how we’ve done so far: 🔓 Premium Content Begins Here 🔒 In today's Premium Section: we're giving a quick update on our first addition in the quantum space, with our initial write-up and the exact conditions that triggered our buy alert. I hope you’ve been paying attention because many of our picks are currently beating the S&P by up to 4-to-1 over the last 12 months. Most financial newsletters charge $500, $1,000, even $5,000 per year. Why? Because they know they can. I don’t. I built my wealth the old-fashioned way, not by selling subscriptions. That’s why I priced this at $35/month, or $300/year. Not because it’s low quality, but because I don’t need to charge the typical prices other newsletters charge. One good trade, idea, or concept could pay for your next decade of subscriptions. The question isn’t ‘Why is this so cheap?’ The question is, ‘Why would I charge more?’ 👉 Upgrade to Premium Now P.S. If this newsletter were $1,000 per year, you’d have to think about it. You’d weigh your options. You’d analyze the risk. But it’s $30 a month. That’s the price of a bad lunch decision. And remember, just one good idea could pay for your subscription for a decade. 👉 Upgrade to Premium Now Recent comments from Premium Members: Amazing! Moonshot is hands down the best $150 decision I have ever made. Up 64% on TICKER REDACTED (so far). Can't thank you enough for your service, advice, recommendations, insight, and every other positive accolade in the dictionary. Very respectfully and gratefully, CK I’m up 71% in 6 weeks would you recommend adding to this bucket if capital allows? MS Hello Double D, As it happened, I already owned some TICKER REDACTED shares when you recommended the stock. Upon your recommendation, I bought more. All told, I'm up over 70% in a month or two. I greatly appreciate the detailed discussion you and your team provide for your recommendations. Thank you. A happy subscriber, PK I finally got some liquidity I could use and bought the stock as well as March 2026 calls yesterday morning (October 2nd) when it was at $17.80. That is easily the best-timed investment/trade I've ever made, and I have your team's perpetual hard work and research to thank for it. Thanks again for all the hard work. You and your team push out a lot of solid research, and the effort doesn't go unnoticed. It is greatly appreciated, MD Closing at 24% gain, and enough profits to pay for 2yrs of your newsletter. Thank you for this! I especially appreciate you detailing the rationale behind your picks. As a newer investor it’s important for me to know why just as much as what. MS Up 68.87% on TICKER REDACTED to date, great recommendation! BW Thanks for the great tip on TICKER REDACTED! I bought, and just eight trading days later, it's up 52% as of this very minute. I'm new to your newsletter, less than two months, but I have found it to be quite soundly researched and a truly invaluable source. I've been actively investing for many years and have, at one time or another, subscribed to various investment advisors. None have been as useful (nor as affordable!) as the Moonshot Minute. You, sir, do excellent work and we individual investors much appreciate it. SD Up 66%! Thanks. SB Kudos and thank you for the TICKER REDACTED recommendation. TICKER REDACTED has been awesome and I do understand/believe this to possibly be only the beginning. I bought 200 shares at $16 and another 100 at $18, the day before the surge started. Again, I am very grateful. RH I've only been with you a few weeks now, and overall, my portfolio is up 41%. Couldn't have done it without you, DD. Thanks again. HJP I joined your plan about 2 months ago. TICKER REDACTED was a real hit - and I did fully realize it yesterday for a rise - 141%. Great deal!! IS Just wanted to drop you a quick THANK YOU! Been a member for about a week (I wanted to see your picks for the electrical asymmetry) and I picked up some TICKER REDACTED & TICKER REDACTED. I’m already up $1,300.00 so my membership is covered for 5 years in about a week! Keep up the great work! Again, THANKS! Glad to be a subscriber! RH 👉 Upgrade to Premium Now   Update your email preferences or unsubscribe here © 2026 Moonshot Minute 228 Park Ave S, #29976, New York, New York 10003, United States Terms of Service